Profili Genici e Personalizzazione del trattamento adiuvante nel carcinoma mammario G. RICCIARDI

Size: px
Start display at page:

Download "Profili Genici e Personalizzazione del trattamento adiuvante nel carcinoma mammario G. RICCIARDI"

Transcription

1 Profili Genici e Personalizzazione del trattamento adiuvante nel carcinoma mammario G. RICCIARDI UOC Oncologia Medica, A.O. Papardo, Messina Dir. Prof. V. Adamo

2 BREAST CANCER Brain Adjuvant Medical Therapies Lung Liver Bone Localized Disease Curable But risk of: Overtreatment Undertreatment Wrog treatment Suboptimal treatment Generalized Disease Very difficult to cure Adapted by M. Piccart AACR 2016

3 Treatment Individualization 100 BC patients 20% HER2+ BC 15% TN BC 65 HR+/HER2- BC patients 5% >4 Node positive 2-3% too frail for CT 50 HR+/HER2- BC PATIENTS POTENTIALLY CANDIDATE TO ADJUVANT CHEMOTHERAPY BENEFIT/NO TOXICITY BENEFIT/TOXICITY NO BENEFIT/NO TOXICITY NO BENEFIT/TOXICITY

4 St Gallen Definition Risk Low G1, T 2, N -; ER & PgR + HER2 ; LVI Absent Only 20% of patienst! R I S k Intermedie High Age <35, G2-3; T>2, Node or Node + (1-3), ER & PgR+, HER2 - Node + (1-3), HER2+, Node + (>4) Most difficult group for CT decision! R I S k

5 Adjuvant Chemotherapy in Early Breast Cancer: Benefit/Risk Balance Benefit Increase Survival (2 to12%) Long-Term Risks Secondary Cancer Cardiac toxicity Early Menopause Reduction cognitive function and Socio-Economic Burden Adpted by M. Piccart AACR 2016

6 The Road To Treatment Individualization QUESTION WHO CAN BE SPARED TREATMENT? WHO SHOULD RECEIVE TREATMENT? CLINICAL PROBLEM AVOID UNNECESSARY Tx MAXIMIZE BENEFIT TOOL PROGNOSTIC MARKERS PREDICTIVE MARKERS INDIVIDUALIZED TREATMENT CHOICE

7 Evaluation of Gene-Expression Profiles Analytic Validity Clinical validity Correlation of score with outcome Refers to the ability to accurately and reliably measure the genotype of interest. is the ability of a test result to divide a population into two or more groups that differ either biologically or clinically Clinical utility Refers to whether using the test leads to an improvement in clinical decision-making, with measurable improvements in clinical outcomes compared with those observed when the test is not used Kwa M, Nat Rev Clin Oncol 2017

8 Most Common Commercially Available Prognostic Gene Signatures for Breast Cancer *FDA Approval: Mammaprint & PAM50 ROR Kwa M, Nat Rev Clin Oncol 2017

9 Early Breast Cancer HR+/HER2- We can identify a subset of patients who do not require adjuvant chemotherapy? YES!

10 Predicting Baseline Prognosis All tests have at least level IB evidence for HR+/HER2-, T1-2 and N0-1 early BC MammaPrint OncotypeDX PAM50 ROR EndoPredict Vijver NEJM 2002 Paik NEJM 2006 Dowsett JCO 2013 Filipits CCR 2011 DATA FROM PROSPECTIVE RANDOMIZED TRIALS (include tumor size+nodal status) Analytical Validation of Decentralized Gene Expression-based tests (only EndoPredict and PROSIGNA)

11 ONCOTYPE DX It was developed on the basis of the NSABP B-20 and B-14 trials.the RS is a continuous variable, ranging from 0 to100,and classified the pts into three categories, ilow risk (RS,18),intermediate risk(rs18-31),and high risk(rs.31), The optimal management of the intermediate-risk group is uncertain and is being studied in the TailorX trial, in which patients with ER+ N0 were assigned to low-risk (RS, 11), intermediaterisk (RS 11-25), and high-risk groups(rs.25).the main results of the intermediate-risk score group are eagerly awaited. 1. Paik S, NEJM 2004, 2.Sparano JA, NEJM2015; 3.Paik S, JCo2006; 4. Albain KS, Lancet 2010; 5.Dowsett M, JCO 2010; 6. Kraw, Nat Rev Clin Oncol 2017

12 Trial Assigning Individualized Options for Treatment or TAILORx

13 TailorX: prognosis of RS low patients 5yrs rate 93.8% (95% CI, 92.4 to 94.9) 5yrs rate 99.3% (95% CI, 98.7 to 99.6) 5yrs rate 98.7% (95% CI, 97.9 to 99.2) 5 yrs rate 98.0% (95% CI, 97.1 to 98.6) Sparano JA et al. N Engl J Med 2015

14

15 PlanB: Translational subprotocol <br />5-year DFS in per-protocol population<br />(no chemotherapy in pn0-1 and Recurrence Score 0-11)

16 MAMMAPRINT The MammaPrint, was the first microarray-based prognostic signature to be approved by the U.S. FDA. The 70-gene profile may be used for determining the prognosis of patients with stage I and/or II, N0 as well as for nodes 1 to 3 positive disease.this gene profile was first established using RNA from fresh, frozen tumor tissues;however from 2012 onward, It is also evaluable in formalin-fixed, paraffin-embedded tumor tissue. A list of 70 genes that could accurately predict poor versus good prognosis for these patients was identified by a supervised analysis of 25,000 genes included in the microarrays. The true clinical utility of MammaPrint is being tested in a randomized prospective phase III trial: MINDACT 1. Sapino A, J Mol Diagn 2014; 2.Mook S, Breast Cancer Res Treat 2009; 3.Knauer M, Breast Cancer Res Treat 2009; 4 Van de Vijver NEJM 2012., 5. Knaw Nat Rev Clin Oncol 2017

17 MINDACT Cardoso F, NEJM 2016

18 The primary end point was survival without distant metastasis (event-free rate at 5 years) Survival without distant metastasis of 94.7% among pts who did not received chemotherapy 95% CI: ); thus, the primary objective of the study (i.e., to show whether the lower boundary of the 95% CI for the rate of survival without distant metastasis would be at least 92%) was achieved. Among women with early-stage breast cancer who were at high clinical risk and low genomic risk for recurrence, the receipt of no chemotherapy on the basis of the 70-gene signature led to a 5-year rate of survival without distant metastasis that was 1.5 percentage points lower than the rate with chemotherapy. Given these findings, approximately 46% of women with breast cancer who are at high clinical risk might not require chemotherapy Cardoso F, NEJM 2016

19 Tryfonidis K, ESMO 2017

20 DMFS at 5-years DFS at 5-years OS at 5-years Tryfonidis K, ESMO 2017

21 PAM50 (PROSIGNA) PAM 50 was originally developed for intrinsic subtyping of breast cancer, but later it started to be used to predict recurrence. Its score, PAM 50 ROR is calculated by using the expression profile of 50 selected genes from four intrinsic subtypes, a proliferation score (18-gene subset), and pathologic tumor size and nodal status. It can be used with formalinfixed, paraffin-embedded tissue samples and was approved by the U.S. FDA in The results of ATAC and ABCSG-8 meet this high level of evidence (Level I) for clinical validity using archived specimens. It is, therefore, a more useful signature to predict late distant relapses compared with Oncotype DX or MammaPrint. 1. Parker JS, JCO 2009; 2.Gnant M, Ann of Oncol 2014; Filipits M, Clin Cancer Res 2014; Coates, Ann of Oncol 2015.

22 ENDOPREDICT The Endopredict analyzed 12 genes with the qrt-pcr for the classification of patients into two recurrence risk groups. The assay was validated in the ABCSG-6 and ABCSG-8 trials. Additionally, EndoPredictClin, which combines the EndoPredict score with tumor size and nodal status in a linear model, identified a subgroup of pts with an excellent long-term prognosis after a standard 5 years of endocrine therapy, thus making it useful for evaluating risk of late elapse.relative gene expression levels are used to calculate the EndoPredict score (EP score) ranging from 0 to 15. Patients with a score below or equal to 5 are classified as low risk for distant recurrence under endocrine therapy, those with a score above 5 as high risk. 1. Filiptis M, Clin Cancer Res 2011; 2. Dubsky P, Br J Cancer. 2013

23 HR+/HER2-neg and NODE-negative INDICATION Evidence Quality Recommendation Strenght OncotypeDX YES HIGH STRONG PAM50 ROR YES HIGH STRONG EndoPredict YES INTERMEDIATE MODERATE MammaPrint YES NO INTERMEDIATE HIGH MODERATE STRONG HR+/HER2-neg and NODE-positive MINDACT : MammaPrint assay may be used in those with high clinical risk INDICATION Evidence Quality Recommendation Strenght OncotypeDX NO INTERMEDIATE MODERATE PAM50 ROR NO INTERMEDIATE MODERATE EndoPredict NO INSUFFICIENT MODERATE MammaPrint NO INTERMEDIATE MODERATE *could be considered in low burden nodal status. 1.Harris L. J Clin Oncol 2016; 2. Krop I., J Clin Onco 2017

24 Early Breast Cancer HR+/HER2- we can identify with the Ki-67 a low-risk group that does not need chemotherapy? NO

25 Confusion Regarding Ki67 Scoring in the Clinical Setting St Gallen 2009 Ki67 was not taken into account Goldhirsch A, Ann of Oncol 2009 St Gallen 2011 Goldhirsch A, Ann of Oncol 2011 A majority of the Panel voted that a threshold of 14% was indicative of high Ki-67 status St Gallen 2013 Goldhirsch A, Ann of Oncol 2013 A majority of the Panel voted that a threshold of 20% was indicative of high Ki-67 status St Gallen 2015 Coates A, Ann of Oncol 2015 St Gallen 2017 Curigliano G, Ann of Oncol 2017 Ki-67 scores should be interpreted in the light of local laboratory values: as an example, if a laboratory has a median Ki-67 score in HR+ disease of 20%, values of 30% or above could be considered clearly high; those of 10% or less clearly low The Panel raised an issue of caution about reproducibility of IHC for Ki67 and its use to make clinical decisions, due to the variability of this assay

26 Guide choice on adjuvant chemotherapy INDICATION Evidence Quality Recommendation Strenght Ki67 IHC NO INTERMEDIATE MODERATE IHC4 NO INTERMEDIATE MODERATE IHC for Ki-67 analysis lacks reproducibility across laboratories and, therefore, cannot be consistently interpreted when performed in a broad range of laboratories J Clin Oncol 2016

27 What if the Prognostic Gene Signatures are inserted into clinical practice? Changes the choice of adjuvant treatment?

28 After receiving the GEP results, treatment recommendations were changed for 40 patients (20%) After receipt of the Prosigna results, physician confidence increased in 41.6% of cases. The Prosigna results reinforced the confidence of clinicians in the accuracy of adjuvant therapy selected for the pts. Martin M & Prat A, CMRO 2015

29 Early Breast Cancer HR+/HER2- Can we safely identify patients who do not need endocrine therapy beyond 5 years?

30 Predicting Late Recurrence To identify a group of patients (T1-2/N0-N+ with HR+/HER2- disease That may be spared extended endocrine therapy (5-10 years) due to their low risk of recurrence PAM50 ROR EndoPredic t Sestak JCO 2015 Sestak JNCI 2013 Dubsky BJC 2013 (include tumor size+nodal status)

31 Predicting Late Recurrence ROR was the strongest molecular prognostic factor in predicting late recurrence and discriminating patients into low and high risk for late distant recurrence. However, the St Gallen 2017 did not recommend the use of gene expression signatures for choosing whether to recommend extended adjuvant endocrine treatment, as no prospective data exist and the retrospective data were not considered sufficient to justify the routine use of genomic assays in this setting. 1. Prat A Ann Oncol 2012; 2. Sestak I J Natl Cancer Inst 2013 ; 3. Curigliano G. Ann of Oncol 2017

32 Multigene Tests: Summary of Evidence All provide prognostic information independent of traditional factors 4 tests based on gene expression (Oncotype DX, PAM50 / Prosigna, Endopredict and MammaPrint ) are available in the clinic. They have proven to be highly reproducible : 2 have been accredited FDA/510(k) (PAM50 y MammaPrint). 2 may be performed in local laboratories(pam50 y EndoPredict). Majority validated in ER+/HER2-, N- BC patients, some also found to be prognostic in N1 pts Only OncotypeDx and Mammaprint have been tested in prospective randomized trials (some studies ongoing for other tests). The Ki67 IHC NO has shown the same evidence to identify low-risk patients who do not require adjuvant chemotherapy and another problem related to Ki67 is that of reproducibility IMPORTANT: They should be used with integration of clinical and pathological data (tumor size and lymph node involvement). PAM50 and EndoPredict integrate these data in the report. Oncotype DX does not consider this data in the report. It is unclear whether routine use is improving patients outcome, but data are emerging

33 GRAZIE!

OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER

OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER OVERVIEW OF GENE EXPRESSION-BASED TESTS IN EARLY BREAST CANCER Aleix Prat, MD PhD Medical Oncology Department Hospital Clínic of Barcelona University of Barcelona esmo.org Disclosures Advisory role for

More information

CARCINOMA DELLA MAMMELLA La scelta del trattamento adiuvante: utilità clinica dei tests genomici

CARCINOMA DELLA MAMMELLA La scelta del trattamento adiuvante: utilità clinica dei tests genomici CARCINOMA DELLA MAMMELLA La scelta del trattamento adiuvante: utilità clinica dei tests genomici Dott.ssa Gaia Griguolo DiSCOG-Università di Padova IOV Istituto Oncologico Veneto I.R.C.C.S. Tutor: Prof.

More information

Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA

Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA Gene Signatures in Breast Cancer: Moving Beyond ER, PR, and HER2? Lisa A. Carey, M.D. University of North Carolina USA When Are Biomarkers Ready To Use? Same Rules for Gene Expression Panels Key elements

More information

Session thématisée Les Innovations diagnostiques en cancérologie

Session thématisée Les Innovations diagnostiques en cancérologie 10 èmes Journées Scientifiques du Cancéropôle Nord-Ouest 10-12 mai 2017, Deauville Session thématisée Les Innovations diagnostiques en cancérologie Les signatures multigéniques pronostiques dans le cancer

More information

Adjuvant endocrine therapy (essentials in ER positive early breast cancer)

Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Adjuvant endocrine therapy (essentials in ER positive early breast cancer) Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Experimental Therapeutics Outline Picking optimal adjuvant endocrine

More information

Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011

Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Robert W. Carlson, M.D. Professor of Medicine Stanford University Chair, NCCN Breast Cancer Treatment Guidelines Panel Selection of

More information

Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer

Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Role of Genomic Profiling in (Minimally) Node Positive Breast Cancer Kathy S. Albain, MD, FACP Professor of Medicine Dean s Scholar Loyola University Chicago Stritch School of Medicine Cardinal Bernardin

More information

Profili di espressione genica

Profili di espressione genica Profili di espressione genica Giampaolo Bianchini MD Ospedale San Raffaele, Milan - Italy Gene expression profiles Transcriptomics Gene DNA mrna mirnas Protein metilation Metabolite Genomics Transcriptomics

More information

Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension?

Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension? Hormone therapyduration: Can weselectthosepatientswho benefitfromtreatmentextension? Ivana Sestak, PhD Centre for Cancer Prevention Wolfson Institute of Preventive Medicine Queen Mary University London

More information

Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint

Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint Assessment of Risk Recurrence: Adjuvant Online, OncotypeDx & Mammaprint William J. Gradishar, MD Professor of Medicine Robert H. Lurie Comprehensive Cancer Center of Northwestern University Classical

More information

A new way of looking at breast cancer tumour biology

A new way of looking at breast cancer tumour biology A new way of looking at breast cancer tumour biology Contents Intrinsic subtypes of breast cancer 3 Gene expression assays 3 Basis of the Prosigna test 4 Information provided by Prosigna 5 The accuracy

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System

More information

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY

Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides

More information

Contemporary Classification of Breast Cancer

Contemporary Classification of Breast Cancer Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline

More information

Breast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)

Breast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive

More information

Genomic platforms in breast cancer

Genomic platforms in breast cancer Genomic platforms in breast cancer Prof. Miguel Martín Instituto de Investigación Sanitaria Hospital Gregorio Marañón Universidad Complutense Madrid mmartin@geicam.org Disclosure Dr. Martin has received

More information

8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview

8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay

More information

38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %

38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI % 38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype

More information

Principles of breast radiation therapy

Principles of breast radiation therapy ANZ 1601/BIG 16-02 EXPERT ESMO Preceptorship Program 2017 Principles of breast radiation therapy Boon H Chua Professor Director of Cancer and Haematology Services UNSW Sydney and Prince of Wales Hospital

More information

She counts on your breast cancer expertise at the most vulnerable time of her life.

She counts on your breast cancer expertise at the most vulnerable time of her life. HOME She counts on your breast cancer expertise at the most vulnerable time of her life. Empowering the right treatment choice for better patient outcomes. The comprehensive genomic assay experts trust.

More information

30 years of progress in cancer research

30 years of progress in cancer research Breast Cancer Molecular Knowledge Integrated in Clinical Practice Personalized Medicine Laura J. Esserman UCSF Comprehensive Cancer Center Retreat Breast Cancer Management Advances 80-90s 1) Screening

More information

Learning Objectives. Financial Disclosure. Breast Cancer Quality Improvement Project with Oncotype DX. Nothing to disclose

Learning Objectives. Financial Disclosure. Breast Cancer Quality Improvement Project with Oncotype DX. Nothing to disclose Breast Cancer Quality Improvement Project with Oncotype DX Denise Johnson Miller, MD, FACS Medical Director Breast Surgery Hackensack Meridian Health Legacy Meridian (Jersey Shore University Medical Center,

More information

Reliable Evaluation of Prognostic & Predictive Genomic Tests

Reliable Evaluation of Prognostic & Predictive Genomic Tests Reliable Evaluation of Prognostic & Predictive Genomic Tests Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov Different Kinds of Biomarkers Prognostic

More information

Rationale For & Design of TAILORx. Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York

Rationale For & Design of TAILORx. Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York Rationale For & Design of TAILORx Joseph A. Sparano, MD Albert Einstein College of Medicine Montefiore-Einstein Cancer Center Bronx, New York Declining Breast Cancer Mortality & Event Rates in Adjuvant

More information

Clinical utility of multigene profiling assays in early-stage breast cancer

Clinical utility of multigene profiling assays in early-stage breast cancer PRACTICE GUIDELINE CLINICAL UTILITY OF MULTIGENE PROFILING ASSAYS, Chang et al. Clinical utility of multigene profiling assays in early-stage breast cancer M.C. Chang md phd,* L.H. Souter phd, S. Kamel-Reid

More information

TABLE OF CONTENTS. Executive Summary The EndoPredict Test Intended Use Population Breast Cancer Clinical Dilemma. Analytical Validity

TABLE OF CONTENTS. Executive Summary The EndoPredict Test Intended Use Population Breast Cancer Clinical Dilemma. Analytical Validity Clinical Dossier TABLE OF CONTENTS Executive Summary The EndoPredict Test Intended Use Population Breast Cancer Clinical Dilemma 1 2 3 Analytical Validity 4 Clinical Validity 4 Clinical Utility 7 Medicare

More information

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer

Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors

More information

The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer

The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate

More information

Relevancia práctica de la clasificación de subtipos intrínsecos en cáncer de mama Miguel Martín Instituto de Investigación Sanitaria Gregorio Marañón

Relevancia práctica de la clasificación de subtipos intrínsecos en cáncer de mama Miguel Martín Instituto de Investigación Sanitaria Gregorio Marañón Relevancia práctica de la clasificación de subtipos intrínsecos en cáncer de mama Miguel Martín Instituto de Investigación Sanitaria Gregorio Marañón Universidad Complutense Madrid The new technologies

More information

FEP Medical Policy Manual

FEP Medical Policy Manual FEP Medical Policy Manual Effective Date: April 15, 2017 Related Policies: None Assays of Genetic Expression in Tumor Tissue as a Technique to Description Laboratory tests have been developed that detect

More information

MammaPrint Improving treatment decisions in breast cancer Support and Involvement of EU

MammaPrint Improving treatment decisions in breast cancer Support and Involvement of EU MammaPrint Improving treatment decisions in breast cancer Support and Involvement of EU 1 Bas van der Baan VP Clinical Affairs Irvine, California Amsterdam, The Netherlands 2 Two Crucial Questions in Cancer

More information

The Oncotype DX Assay A Genomic Approach to Breast Cancer

The Oncotype DX Assay A Genomic Approach to Breast Cancer The Oncotype DX Assay A Genomic Approach to Breast Cancer Pathology: 20 th and 21 st Century Size Age Phenotype Nodal status Protein/Gene Genomic Profiling Prognostic & Predictive Markers Used in Breast

More information

1 INTRODUCTION REVIEW ARTICLE

1 INTRODUCTION REVIEW ARTICLE Received: 12 December 2016 Revised: 15 December 2016 Accepted: 15 December 2016 DOI 10.1002/jso.24561 REVIEW ARTICLE Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical

More information

The Current Status and the Future Prospects of Multigene testing in Europe

The Current Status and the Future Prospects of Multigene testing in Europe The Current Status and the Future Prospects of Multigene testing in Europe Emiel J. Rutgers The Netherlands Cancer Institute Antoni Van Leeuwenhoek Hospital Amsterdam St. Gallen Recommendations 2009 =

More information

National Medical Policy

National Medical Policy National Medical Policy Subject: Policy Number: MammaPrint, Prosigna and Other Gene Expression Tests for Breast Cancer NMP520 Effective Date*: May 2013 Updated: June 2017 This National Medical Policy is

More information

Kathy Albain, MD. Chemotherapy in Luminal Breast Cancer: Who Benefits? Loyola University Chicago Stritch School of Medicine

Kathy Albain, MD. Chemotherapy in Luminal Breast Cancer: Who Benefits? Loyola University Chicago Stritch School of Medicine Chemotherapy in Luminal Breast Cancer: Who Benefits? Kathy Albain, MD Loyola University Chicago Stritch School of Medicine, Director, Breast Clinical Research Program, Cardinal Bernardin Cancer Center,

More information

MP Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients With Breast Cancer. Related Policies None

MP Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients With Breast Cancer. Related Policies None Medical Policy Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients With Breast BCBSA Ref. Policy: 2.04.36 Last Review: 11/15/2018 Effective Date: 02/15/2019 Section:

More information

EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino

EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT

More information

Adjuvan Chemotherapy in Breast Cancer

Adjuvan Chemotherapy in Breast Cancer Adjuvan Chemotherapy in Breast Cancer Prof Dr Adnan Aydıner Istanbul University, Oncology Institute aa1 Slide 1 aa1 adnan aydiner; 17.02.2008 15-Year Reductions in Recurrence and Disease-Specific Mortality

More information

DIAGNOSTICS ASSESSMENT PROGRAMME

DIAGNOSTICS ASSESSMENT PROGRAMME DIAGNOSTICS ASSESSMENT PROGRAMME Evidence overview Tumour profiling tests to guide adjuvant chemotherapy decisions in people with breast cancer (update of DG10) This overview summarises the key issues

More information

TAILORx: Established and Potential Implications for Clinical Practice

TAILORx: Established and Potential Implications for Clinical Practice TAILORx: Established and Potential Implications for Clinical Practice Joseph A. Sparano, MD Study Chair, TAILORx Vice-Chair, ECOG-ACRIN Cancer Research Group Hello Healthcare Summit Berlin, Germany March

More information

MammaPrint, the story of the 70-gene profile

MammaPrint, the story of the 70-gene profile MammaPrint, the story of the 70-gene profile René Bernards Professor of Molecular Carcinogenesis The Netherlands Cancer Institute Amsterdam Chief Scientific Officer Agendia Amsterdam The breast cancer

More information

I test molecolari nei protocolli di diagnosi e di trattamento

I test molecolari nei protocolli di diagnosi e di trattamento I test molecolari nei protocolli di diagnosi e di trattamento Anna Sapino IRCCs Candiolo Dip Scienze Mediche, Università degli Studi di Torino 2016: Pathological report of breast cancer MINIMAL REQUIREMENTS

More information

A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer

A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage Breast Cancer Adv Ther (2015) 32:1237 1247 DOI 10.1007/s12325-015-0269-2 ORIGINAL RESEARCH A Prospective Comparison of the 21-Gene Recurrence Score and the PAM50-Based Prosigna in Estrogen Receptor-Positive Early-Stage

More information

Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast International Group (BIG aisbl), Chair ESMO President

Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast International Group (BIG aisbl), Chair ESMO President Symposium «Evaluation of the Belgian Cancer Plan» Brussels, November 26th, 2012 Personalized oncology in Europe: only a dream if national health systems do not get involved in diagnostics and pivotal cancer

More information

Reporting of Breast Cancer Do s and Don ts

Reporting of Breast Cancer Do s and Don ts Reporting of Breast Cancer Do s and Don ts 7 th SGH Annual Breast Pathology Course Professor Michael Bilous Conjoint Professor Western Sydney University Consultant Pathologist, Australian Clinical Labs,

More information

MEDICAL POLICY. SUBJECT: GENETIC ASSAY OF TUMOR TISSUE TO DETERMINE PROGNOSIS OF BREAST CANCER (OncotypeDX TM, MammaPrint )

MEDICAL POLICY. SUBJECT: GENETIC ASSAY OF TUMOR TISSUE TO DETERMINE PROGNOSIS OF BREAST CANCER (OncotypeDX TM, MammaPrint ) MEDICAL POLICY PAGE: 1 OF: 8 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.

More information

Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer

Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Medical Policy Manual Genetic Testing, Policy No. 42 Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Next Review: December 2018 Last Review:

More information

GENOMIC TESTS FOR BREAST CANCER: FACT, MYTH, AND EVERYTHING IN BETWEEN

GENOMIC TESTS FOR BREAST CANCER: FACT, MYTH, AND EVERYTHING IN BETWEEN GENOMIC TESTS FOR BREAST CANCER: FACT, MYTH, AND EVERYTHING IN BETWEEN Adam Brufsky, MD, PhD Professor of Medicine Associate Chief, Hematology-Oncology Associate Director, Clinical Investigation University

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Assays of Genetic Expression in Tumor Tissue as a Technique Page 1 of 67 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Assays of Genetic Expression in Tumor Tissue

More information

ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA

ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)

More information

Evolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology

Evolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic

More information

Adjuvant Endocrine Therapy: How Long is Long Enough?

Adjuvant Endocrine Therapy: How Long is Long Enough? Adjuvant Endocrine Therapy: How Long is Long Enough? Harold J. Burstein, MD, PhD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts hburstein@partners.org I have no conflicts to

More information

Breast Cancer Assays of Genetic Expression in Tumor Tissue

Breast Cancer Assays of Genetic Expression in Tumor Tissue Breast Cancer Assays of Genetic Expression in Tumor Tissue Policy Number: Original Effective Date: MM.12.009 12/02/2008 Line(s) of Business: Current Effective Date Section: 05/25/2018 Other Miscellaneous

More information

Janet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE. August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario

Janet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE. August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario Janet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario Session: Correlative Studies in Phase III Trials Title: Design

More information

Oncotype DX testing in node-positive disease

Oncotype DX testing in node-positive disease Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype

More information

Breast cancer classification: beyond the intrinsic molecular subtypes

Breast cancer classification: beyond the intrinsic molecular subtypes Breast cancer classification: beyond the intrinsic molecular subtypes Britta Weigelt, PhD Signal Transduction Laboratory CRUK London Research Institute Summary Breast cancer heterogeneity Molecular classification

More information

Comparison of prognostic signatures for ER positive breast cancer in TransATAC:

Comparison of prognostic signatures for ER positive breast cancer in TransATAC: Comparison of prognostic signatures for ER positive breast cancer in TransATAC: EndoPredict, a high performance test in node negative and node positive disease Ivana Sestak, PhD Centre for Cancer Prevention

More information

Breast Cancer Assays of Genetic Expression in Tumor Tissue

Breast Cancer Assays of Genetic Expression in Tumor Tissue Breast Cancer Assays of Genetic Expression in Tumor Tissue Policy Number: Original Effective Date: MM.12.009 12/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/16/2016

More information

Current Status and Future Development of Tools for Prognosis and Prediction - USA

Current Status and Future Development of Tools for Prognosis and Prediction - USA Current Status and Future Development of Tools for Prognosis and Prediction - USA John H. Ward, MD Professor of Medicine University of Utah School of Medicine Huntsman Cancer Institute October18, 2009

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our

More information

11th Annual Population Health Colloquium. Stan Skrzypczak, MS, MBA Sr. Director, Marketing Genomic Health, Inc. March 15, 2011

11th Annual Population Health Colloquium. Stan Skrzypczak, MS, MBA Sr. Director, Marketing Genomic Health, Inc. March 15, 2011 11th Annual Population Health Colloquium Stan Skrzypczak, MS, MBA Sr. Director, Marketing Genomic Health, Inc. March 15, 2011 Agenda Personalized medicine in oncology healthcare Clinical relevance of personalized

More information

Considerations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology

Considerations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment

More information

The Role of Novel Assays in the Prediction of Benefit from Extended Adjuvant Endocrine Therapy for Breast Cancer

The Role of Novel Assays in the Prediction of Benefit from Extended Adjuvant Endocrine Therapy for Breast Cancer The Role of Novel Assays in the Prediction of Benefit from Extended Adjuvant Endocrine Therapy for Breast Cancer Erin Roesch, MD, and Claudine Isaacs, MD Abstract Endocrine therapy in the adjuvant setting

More information

What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland

What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer

More information

Late Recurrence and Death in ER Positive Early Stage Breast Cancer The Next Frontier. Daniel F. Hayes, MD, FASCO, FACP Breast Oncology Program

Late Recurrence and Death in ER Positive Early Stage Breast Cancer The Next Frontier. Daniel F. Hayes, MD, FASCO, FACP Breast Oncology Program Late Recurrence and Death in ER Positive Early Stage Breast Cancer The Next Frontier Daniel F. Hayes, MD, FASCO, FACP Breast Oncology Program Conflicts of Interest Research Funding Menarini/Silicon Biosystems(Manufacturer

More information

Extended Hormonal Therapy

Extended Hormonal Therapy Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early

More information

Luminal A and B Where are we? (or lost in translation?)

Luminal A and B Where are we? (or lost in translation?) Luminal A and B Where are we? (or lost in translation?) Emiel J. Rutgers The Netherlands Cancer Institute Antoni Van Leeuwenhoek Hospital Amsterdam How to determine adjuvant or neoadjuvant treatment for

More information

William J. Gradishar MD

William J. Gradishar MD Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley

More information

Alternate Gene Signatures, or Not

Alternate Gene Signatures, or Not Charles M. Perou, Ph.D. Departments of Genetics and Pathology Lineberger Comprehensive Cancer Center University of North Carolina Chapel Hill, North Carolina, USA Alternate Gene Signatures, or Not Charles

More information

RNA preparation from extracted paraffin cores:

RNA preparation from extracted paraffin cores: Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.

More information

Sesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015

Sesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015 Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant

More information

The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer

The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia

More information

Is Gene Expression Profiling the Best Method for Selecting Systemic Therapy in EBC? Norman Wolmark Miami March 8, 2013

Is Gene Expression Profiling the Best Method for Selecting Systemic Therapy in EBC? Norman Wolmark Miami March 8, 2013 Is Gene Expression Profiling the Best Method for Selecting Systemic Therapy in EBC? Norman Wolmark Miami March 8, 2013 Changing Phases claudin low Lum A Lum B Basal Her2 NIH Consensus Development Panel,

More information

THE 21-GENE RECURRENCE SCORE: BEATSON WEST OF SCOTLAND CANCER CENTRE EXPERIENCE. Dr Husam Marashi 03/02/2017

THE 21-GENE RECURRENCE SCORE: BEATSON WEST OF SCOTLAND CANCER CENTRE EXPERIENCE. Dr Husam Marashi 03/02/2017 THE 21-GENE RECURRENCE SCORE: BEATSON WEST OF SCOTLAND CANCER CENTRE EXPERIENCE Dr Husam Marashi 03/02/2017 THE 21-GENE RECURRENCE SCORE: BEATSON WEST OF SCOTLAND CANCER TODAY S TALK: CENTRE EXPERIENCE

More information

Biologic Subtypes and Prognos5c Factors. Claudine Isaacs, MD Georgetown University

Biologic Subtypes and Prognos5c Factors. Claudine Isaacs, MD Georgetown University Biologic Subtypes and Prognos5c Factors Claudine Isaacs, MD Georgetown University Prognos5c Factor Defini5on Predicts outcome in absence of systemic therapy Thus tell us when (not how) to treat a pa5ent

More information

Type: Evidence Based Evidence Quality: High Strength of Recommendation: Strong

Type: Evidence Based Evidence Quality: High Strength of Recommendation: Strong Clinical Question 1: For women with early-stage invasive breast cancer and with known estrogen and progesterone receptor (ER/PgR) and human epidermal growth factor receptor 2 (HER2 status), which other

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Assays of Genetic Expression in Tumor Tissue as a Technique Page 1 of 55 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Assays of Genetic Expression in Tumor Tissue

More information

Breast cancer pathology

Breast cancer pathology Breast cancer pathology Giancarlo Pruneri, M.D. National Cancer Institute (INT) Milan University of Milan, School of Medicine Giancarlo.Pruneri@unimi.it Currently accepted prognostic/predictive parameters

More information

The TAILORx Trial: A review of the data and implications for practice

The TAILORx Trial: A review of the data and implications for practice The TAILORx Trial: A review of the data and implications for practice Angela DeMichele, MD, MSCE Jill & Alan Miller Endowed Chair in Breast Cancer Excellence Professor of Medicine and Epidemiology University

More information

Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers. Richard Simon, J Clin Oncol 23:

Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers. Richard Simon, J Clin Oncol 23: Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers. Richard Simon, J Clin Oncol 23:7332-7341 Presented by Deming Mi 7/25/2006 Major reasons for few prognostic factors to

More information

FISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC

FISH mcgh Karyotyping ISH RT-PCR. Expression arrays RNA. Tissue microarrays Protein arrays MS. Protein IHC Classification of Breast Cancer in the Molecular Era Susan J. Done University Health Network, Toronto Why classify? Prognosis Prediction of response to therapy Pathogenesis Invasive breast cancer can have

More information

Postoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital

Postoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age

More information

The 70-Gene Signature (MammaPrint) As a Guide for the Management of Early Stage Breast Cancer. California Technology Assessment Forum

The 70-Gene Signature (MammaPrint) As a Guide for the Management of Early Stage Breast Cancer. California Technology Assessment Forum TITLE: The 70-Gene Signature (MammaPrint) As a Guide for the Management of Early Stage Breast Cancer AUTHOR: Jeffrey A. Tice, MD Assistant Professor of Medicine Division of General Internal Medicine Department

More information

Section: Genetic Testing Last Reviewed Date: March Policy No: 42 Effective Date: June 1, 2014

Section: Genetic Testing Last Reviewed Date: March Policy No: 42 Effective Date: June 1, 2014 Medical Policy Manual Topic: Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis In Patients With Breast Cancer Date of Origin: October 5, 2004 Section: Genetic Testing Last

More information

Early Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center

Early Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10

More information

Genomic Profiling of Tumors and Loco-Regional Recurrence

Genomic Profiling of Tumors and Loco-Regional Recurrence 1 Genomic Profiling of Tumors and Loco-Regional Recurrence Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,

More information

III Congreso Internacional de Oncologia del Interior XII Jornadas de Oncologia del Interior Cordoba Argentina. Farmacogenomica y Cancer de Mama

III Congreso Internacional de Oncologia del Interior XII Jornadas de Oncologia del Interior Cordoba Argentina. Farmacogenomica y Cancer de Mama III Congreso Internacional de Oncologia del Interior XII Jornadas de Oncologia del Interior Cordoba Argentina Farmacogenomica y Cancer de Mama Vicente Valero, M.D., F.A.C.P. Professor of Medicine Deputy

More information

Oncotype DX MM /01/2008. HMO; PPO; QUEST 03/01/2014 Section: Other/Miscellaneous Place(s) of Service: Office

Oncotype DX MM /01/2008. HMO; PPO; QUEST 03/01/2014 Section: Other/Miscellaneous Place(s) of Service: Office Oncotype DX Policy Number: Original Effective Date: MM.12.009 12/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 03/01/2014 Section: Other/Miscellaneous Place(s) of Service: Office

More information

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers 日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Assays of Genetic Expression in Tumor Tissue as a Technique Page 1 of 54 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Assays of Genetic Expression in Tumor Tissue

More information

Oncotype DX reveals the underlying biology that changes treatment decisions 37% of the time

Oncotype DX reveals the underlying biology that changes treatment decisions 37% of the time Oncotype DX reveals the underlying biology that changes treatment decisions 37% of the time Even when treatment decisions based on traditional measures seem conclusive, Oncotype DX can lead to a different

More information

pat hways Medtech innovation briefing Published: 25 March 2015 nice.org.uk/guidance/mib27

pat hways Medtech innovation briefing Published: 25 March 2015 nice.org.uk/guidance/mib27 pat hways The Prosigna gene expression profiling assay for assessing long-term risk of breast cancer recurrence Medtech innovation briefing Published: 25 March 2015 nice.org.uk/guidance/mib27 Summary The

More information

A breast cancer gene signature for indolent disease

A breast cancer gene signature for indolent disease Breast Cancer Res Treat (2017) 164:461 466 DOI 10.1007/s10549-017-4262-0 EPIDEMIOLOGY A breast cancer gene signature for indolent disease Leonie J. M. J. Delahaye 1 Caroline A. Drukker 2,3 Christa Dreezen

More information

Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer

Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Policy Number: 2.04.36 Last Review: 9/2018 Origination: 1/2006 Next Review: 9/2019 Policy

More information

Emerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer

Emerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Assays of Genetic Expression in Tumor Tissue as a Technique Page 1 of 47 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Assays of Genetic Expression in Tumor Tissue

More information

Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer

Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Policy Number: 2.04.36 Last Review: 1/2019 Origination: 1/2006 Next Review: 9/2019 Policy

More information

Medical Policy. Description. Related Policies. Policy. Effective Date January 1, 2015 Original Policy Date December 1, 2005

Medical Policy. Description. Related Policies. Policy. Effective Date January 1, 2015 Original Policy Date December 1, 2005 2.04.36 Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date January

More information

Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives

Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast

More information